Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 751 to 765 of 1505 results for patients and public

  1. Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (IPG773)

    Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.

  2. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

  3. Transcranial direct current stimulation (tDCS) for depression (IPG530)

    Evidence-based recommendations on transcranial direct current stimulation (tDCS) for depression. This involves electrical stimulation of the brain by applying a weak direct current to the scalp.

  4. Laparoscopic removal of uterine fibroids with power morcellation (IPG703)

    Evidence-based recommendations on laparoscopic removal of uterine fibroids with power morcellation in adults. This involves cutting the fibroids into small pieces to remove them.

  5. Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair (IPG707)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This involves inserting a bioprosthetic mitral valve into an existing mitral valve ring to treat a leaking mitral valve, without needing repeat open heart surgery.

  6. Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

  7. Workplace health: long-term sickness absence and capability to work (NG146)

    This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.

  8. Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (IPG706)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis in adults. This involves inserting a new valve inside a failed bioprosthetic valve to replace the faulty one without needing repeat open heart surgery.

  9. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    In development Reference number: GID-TA11657 Expected publication date:  07 April 2027

  10. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development Reference number: GID-TA11036 Expected publication date: TBC

  11. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

  12. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

    In development Reference number: GID-TA11742 Expected publication date: TBC

  13. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date: TBC

  14. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    In development Reference number: GID-TA11759 Expected publication date: TBC

  15. Ensitrelvir for treating COVID-19 [ID6231]

    In development Reference number: GID-TA11224 Expected publication date: TBC